Amgen Inc. (NASDAQ:AMGN) Shares Bought by Legacy Wealth Management LLC MS

Legacy Wealth Management LLC MS lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 115.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,936 shares of the medical research company’s stock after acquiring an additional 1,036 shares during the quarter. Legacy Wealth Management LLC MS’s holdings in Amgen were worth $505,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the business. Capital Performance Advisors LLP bought a new position in Amgen during the 3rd quarter valued at $25,000. Strategic Financial Concepts LLC bought a new stake in shares of Amgen during the 2nd quarter valued at about $26,000. Legacy Investment Solutions LLC bought a new stake in Amgen in the third quarter valued at $29,000. Hershey Financial Advisers LLC acquired a new stake in shares of Amgen in the 2nd quarter worth about $30,000. Finally, Matrix Trust Co bought a new position in Amgen in the 3rd quarter worth about $36,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Performance

Shares of AMGN traded down $1.53 during midday trading on Monday, reaching $259.69. 435,427 shares of the stock were exchanged, compared to its average volume of 1,898,890. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The stock’s 50 day simple moving average is $284.63 and its 200 day simple moving average is $310.47. The company has a market cap of $139.59 billion, a P/E ratio of 33.25, a PEG ratio of 2.91 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The company had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. During the same quarter in the previous year, the business earned $4.96 earnings per share. Amgen’s revenue was up 23.2% compared to the same quarter last year. On average, sell-side analysts expect that Amgen Inc. will post 19.53 earnings per share for the current year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be given a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.67%. The ex-dividend date is Friday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio is currently 121.90%.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Dbs Bank upgraded shares of Amgen to a “strong-buy” rating in a report on Monday, September 16th. William Blair reaffirmed an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. StockNews.com lowered Amgen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Citigroup lowered their target price on Amgen from $335.00 to $310.00 in a research note on Wednesday, November 27th. Finally, Barclays raised their price target on shares of Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a report on Monday, October 7th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Amgen currently has a consensus rating of “Hold” and a consensus price target of $318.83.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.